Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.43 USD | +6.63% | -3.61% | -20.56% |
10/05 | UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating | MT |
09/05 | Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.56% | 284.54Cr | |
+6.58% | 11TCr | |
+11.02% | 11TCr | |
-12.74% | 2.22TCr | |
+0.29% | 2.13TCr | |
-4.50% | 1.9TCr | |
-37.85% | 1.85TCr | |
-10.98% | 1.68TCr | |
+38.66% | 1.25TCr | |
-25.44% | 808.97Cr |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- Morgan Stanley Adjusts Price Target on Arrowhead Pharmaceuticals to $37 From $41, Maintains Equal-Weight Rating